AbbVie Inc (ABBV) - Total Liabilities
Based on the latest financial reports, AbbVie Inc (ABBV) has total liabilities worth $108.96 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
AbbVie Inc - Total Liabilities Trend (2010–2025)
This chart illustrates how AbbVie Inc's total liabilities have evolved over time, based on quarterly financial data. See AbbVie Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
AbbVie Inc Competitors by Total Liabilities
The table below lists competitors of AbbVie Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bank of America Corp
NYSE:BAC
|
USA | $3.20 Trillion |
|
Berkshire Hathaway Inc
NYSE:BRK-A
|
USA | $522.82 Billion |
|
Lam Research Corp
NASDAQ:LRCX
|
USA | $10.21 Billion |
|
Caterpillar Inc
NYSE:CAT
|
USA | $77.27 Billion |
|
Chevron Corp
NYSE:CVX
|
USA | $140.18 Billion |
|
Procter & Gamble Company
NYSE:PG
|
USA | $73.97 Billion |
|
GE Aerospace
NYSE:GE
|
USA | $110.15 Billion |
|
The Coca-Cola Company
NYSE:KO
|
USA | $68.48 Billion |
Liability Composition Analysis (2010–2025)
This chart breaks down AbbVie Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ABBV company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.96 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.80 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AbbVie Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AbbVie Inc (2010–2025)
The table below shows the annual total liabilities of AbbVie Inc from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $137.19 Billion | +4.09% |
| 2024-12-31 | $131.80 Billion | +6.02% |
| 2023-12-31 | $124.31 Billion | +2.30% |
| 2022-12-31 | $121.52 Billion | -7.30% |
| 2021-12-31 | $131.09 Billion | -4.64% |
| 2020-12-31 | $137.47 Billion | +41.30% |
| 2019-12-31 | $97.29 Billion | +43.50% |
| 2018-12-31 | $67.80 Billion | +3.21% |
| 2017-12-31 | $65.69 Billion | +6.88% |
| 2016-12-31 | $61.46 Billion | +25.17% |
| 2015-12-31 | $49.10 Billion | +90.54% |
| 2014-12-31 | $25.77 Billion | +4.31% |
| 2013-12-31 | $24.71 Billion | +4.49% |
| 2012-12-31 | $23.64 Billion | +211.57% |
| 2011-12-31 | $7.59 Billion | +39.72% |
| 2010-12-31 | $5.43 Billion | -- |
About AbbVie Inc
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various c… Read more